Pulmonx: 3 Key Takeaways for Long-Term Investors

Pulmonx returned to year-over-year top-line growth with $22.8 million in Q3 2026 revenue, driven by cost reductions that cut operating expenses 18% YoY and focused commercial execution. The company reduced full-year cash burn expectations to $22 million and maintains gross margins above 75%, with management confident in a clear pathway to cash flow breakeven. Market expansion through AeriSeal trials could expand the addressable market by roughly 20% globally.